Quarterly report [Sections 13 or 15(d)]

Segment Reporting (Tables)

v3.25.1
Segment Reporting (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Summary of Operating Costs and Expenses and Interest Expense, Net

 

Three Months Ended

 

 

March 31,

 

 

2025

 

 

2024

 

Segment cost of sales (a)

$

 

 

$

 

Segment research and development (b) (c)

 

(569

)

 

 

(3,877

)

Segment general and administration (b) (c)

 

(2,731

)

 

 

(2,141

)

Share-based compensation expense (see Note 15)

 

(61

)

 

 

(138

)

Depreciation and amortization

 

(349

)

 

 

(7

)

Operating loss

$

(3,710

)

 

$

(6,163

)

 

a)
Amortization expense of $342 related to the Pfizer Intangible asset has been excluded for the three months ended March 31, 2025 and included within depreciation and amortization.
b)
Share-based payment expense of $19 and $96 related to research and development and $42 and $42 related to general and administration have been excluded for the three months ended March 31, 2025 and 2024, respectively, and included within share-based compensation expense.
c)
Depreciation expense of $3 and $4 related to research and development and $4 and $3 related to general and administration have been excluded for the three months ended March 31, 2025 and 2024, respectively, and included within depreciation and amortization.

Interest Expense, Net

 

Three Months Ended

 

 

2025

 

 

2024

 

Interest income

$

152

 

 

$

262

 

Interest expense

 

(686

)

 

 

(749

)

Interest expense, net

$

(534

)

 

$

(487

)

Schedule of Distribution of Long-Lived Assets by Geographical Area

The distribution of long-lived assets by geographical area was as follows:

Long-lived assets

 

March 31, 2025

 

 

December 31, 2024

 

Ireland

 

$

19,417

 

 

$

19,759

 

U.S.

 

 

11

 

 

 

15

 

Total

 

$

19,428

 

 

$

19,774